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Background and purpose: The diagnosis of rare movement disorders is difficult
and specific management programmes are not well defined. Thus, in order to
capture and assess care needs, the European Reference Network for Rare
Neurological Diseases has performed an explorative care need survey across
all European Union (EU) countries.
Methods: This is a multicentre, cross-sectional study. A survey about the
management of different rare movement disorders (group 1, dystonia, paroxys-
mal dyskinesia and neurodegeneration with brain iron accumulation; group 2,
ataxias and hereditary spastic paraparesis; group 3, atypical parkinsonism;
group 4, choreas) was sent to an expert in each group of disorders from each
EU country.
Results: Some EU countries claimed for an increase of teaching courses.
Genetic testing was not readily available in a significant number of countries.
Regarding management, patients’ accessibility to tertiary hospitals, to experts
and to multidisciplinary teams was unequal between countries and groups of dis-
eases. The availability of therapeutic options, such as botulinum toxin or more
invasive treatments like deep brain stimulation, was limited in some countries.
Conclusions: The management of these conditions in EU countries is unequal.
The survey provides evidence that a European care-focused network that is
able to address the unmet rare neurological disease care needs and inequalities
is highly warranted.
Introduction
The definition of rare diseases varies in different coun-
tries, but generally they are considered as those with a
prevalence lower than 5 in 10 000 people [1]. In Eur-
ope, it is estimated that more than 500 000 persons
are affected by rare neurological diseases (RNDs) [2].
Due to their low prevalence, clinicians are often not
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familiar with these conditions and making a prompt
diagnosis is challenging [3]. Moreover, for many dis-
eases, specific management programmes are not well
defined [4]. A global effort is necessary in order to
raise awareness, improve knowledge and create speci-
fic diagnostic and management guidelines.
As a response to this challenge, which is shared by
all rare diseases, European Reference Networks
(ERNs) have been launched in 2017 by the European
Union (EU) Board of Member States. This is a pan-
European initiative to facilitate access to highly spe-
cialized healthcare for patients with rare or low preva-
lence complex diseases and to support the cooperation
of healthcare providers at the European level in the
field of rare diseases.
The European Reference Network for Rare Neuro-
logical Diseases (ERN-RND), one of 24 ERNs, is a
network of the European RND expertise centres. At
present, it has 31 members from 13 countries; how-
ever, through a currently ongoing expansion process,
the ERN-RND will very likely have more than 60
members and be covering the vast majority of EU
countries by the end of 2020. The huge heterogeneity
of RNDs, healthcare systems and socio-economic situ-
ations in Europe, as well as the still limited clinical
expert workforce for RNDs, at a time of rapid
research-driven innovations, means that there is a very
real risk that not all patients with RNDs across Eur-
ope might benefit from improved and emerging
opportunities in diagnosis, care and treatment.
Thus, in order to capture and assess care needs that
the ERN-RND can address, taking into account dis-
ease- as well as country-specific differences, this explo-
rative care need survey was performed for all rare
movement disorders (MDs) covered by the ERN-RND
across all EU countries. Patient representatives have
significantly contributed to the design of the study.
Methodology
Design
This is a multicentre, cross-sectional study. A survey
about the management of different rare MDs designed
by the ERN-RND working group on care coordina-
tion was sent to an expert in each group of disorders
from each EU country.
Groups of movement disorders assessed
Four different groups of rare MDs were studied:
group 1 included dystonia, paroxysmal dyskinesia and
neurodegeneration with brain iron accumulation
(NBIA) (group 1-DYS); group 2, ataxias and
hereditary spastic paraparesis (HSP) (group 2-ATX/
HSP); group 3, atypical parkinsonism such as progres-
sive supranuclear palsy, multiple system atrophy and
corticobasal degeneration (group 3-AP); group 4
included Huntington’s disease (HD) and other choreas
(group 4-C).
Participants
Participants were one expert for each group of disor-
ders and for each EU country. Experts from Norway
and Iceland were also asked, as European countries
outside the EU are also invited to join the ERN-
RND. The experts were chosen because of their exper-
tise in a specific rare MD and also for the prominent
role they play in their management nationally. In
cases of countries without specialists in some of these
disorders, a university neurology hospital with a good
reputation in that country was contacted and the most
appropriate neurologist answered the survey.
Questionnaire
A questionnaire was developed based on a modified
version of the published survey in the study by Valadas
et al. [5], adapted to the current study and tuned to the
respective group of rare MDs. The questionnaire was
divided into three sections: section I, characterization
of participants (i.e. name, qualifications, affiliation and
main research area of interest); section II, characteriza-
tion of the country (i.e. accessibility, training in all
kinds of healthcare providers, network, patient associ-
ations, tertiary centres, ancillary tests, treatment avail-
ability and research); section III was an open question,
asking for the three main measures that, as a personal
opinion of the participants, should be urgently imple-
mented to improve the management on that particular
MD in their specific country. Section II was composed
of close-ended questions (yes/no; easily accessible/satis-
factory or accessible with some difficulty/difficult or
not available/I don’t know). Specific questions about
specific treatments and visits to other specialists for
each group of MDs were also included.
In September 2018, the questionnaire was sent by
email to the participants, including instructions on
how to fill in the form. Up to three reminders were
sent and, in the case of no response, a second expert
was consulted. Recruitment finished on 1 May 2019.
The results were discussed at the ERN-RND annual
meeting in Siena in June 2019.
Ethical statement
Ethical approval was not necessary for this study.
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Statistical analysis
A descriptive analysis was performed. Qualitative vari-
ables are presented as absolute and relative frequen-
cies. The total of responses by group is indicated for
all the items. Data analysis was carried out using
Stata 14.0 (Stata Corp, College Station, TX, USA) for
Windows.
Results
Of the 28 EU countries plus Norway and Iceland, 26
responses were obtained in group 1-DYS, 21
responses in group 2-ATX/HSP, 19 responses in
group 3-AP and 14 responses in group 4-C (Fig. 1). A
total of 80 different respondents with expertise in a
specific MD were approached.
Participants’ characterization
Main research area of interest
The majority of respondents in all the groups were
neurologists and their main area of research interest
was clinical research (42/80), followed by genetics (10/
80) and clinical trials (10/80).
Country’s characterization
Movement disorder global view in each country
Expertise and patients’ accessibility. The accessibility
to MD experts in the groups (79/80) was difficult in
27.8%, satisfactory in 55.7% and easy in 16.5%.
Specifically, the access to MD experts for patients in
group 1-DYS (26/26) was difficult in 26.9%, satisfac-
tory in 50.0% and easy in 23.1%. The access to
Figure 1 Europe map of the surveyed countries for each group of diseases.
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experts in group 2-ATX/HSP (20/21) was difficult in
20.0%, satisfactory in 75.0% and easy in 5.0%. In
group 3-AP (19/19) the access was difficult in 31.6%,
satisfactory in 52.6% and easy in 15.8%. Finally, in
group 4-C (14/14), the accessibility was difficult in
35.7%, satisfactory in 42.9% and easy in 21.4%. The
main reasons for difficult accessibility were the small
number of experts who usually work at university
hospitals or in private institutions with expensive con-
sultations, long waiting lists and lack of knowledge
amongst clinicians.
Training. All countries had MD experts, except Ice-
land, and more than 90% had teaching courses or
symposia in MDs for residents and general neurolo-
gists. Teaching courses in MDs for general practition-
ers were less common, being present in around 50%
of the countries. Specific training in MDs was avail-
able for nurses, physiotherapists and speech therapists
in 40%, 33% and 28% of the countries, respectively.
Countries that claimed for an increase of teaching
courses for neurologists and general medical practi-
tioners were Lithuania, Iceland, Bulgaria, Cyprus, Slo-
vakia, Latvia, Hungary, Romania and Estonia.
Almost all the countries requested teaching courses
for other healthcare providers.
Scientific societies. More than 80% of the countries
had an official MD society or working group.
Answers for each group of disorders
Research. A total of six different types of research
(basic, clinical, genetics, brain banks, neurophysiol-
ogy, imaging) were requested. Clinical research and
genetic research were the most frequent type of
research in groups 1-DYS and 2-ATX/HSP. For
group 3-AP, all kinds of research were similarly pre-
sent, with a slight predominance of clinical research
(68.4%) and neuroimaging studies (52.6%). Finally, in
group 4-C, basic research and clinical studies were the
most common. Anatomopathological research was the
least in all the groups.
Association. In group 1-DYS, more than half (65.4%,
17/26) of the countries had patient associations for
dystonia but not for paroxysmal dyskinesia or NBIA
(7.7% and 15.4%, respectively). In group 2-ATX/
HSP, 52.4% (11/21) of the countries had a national
ataxia/HSP patient association and in group 3-AP the
prevalence was lower (21.4%), especially for patients
with corticobasal degeneration (11.1%, 2/18). All the
responders from group 4-C said that they had
national patient associations.
Management. The proportion of patients who were
evaluated in tertiary centres at least once in the course
of the disease was 68.4% in group 3-AP and approxi-
mately 50% in the others.
In group 1-DYS, 100% (26/26) of the countries had
experts in the field of dystonia, and to a lesser extent
in paroxysmal dyskinesias (88.5%, 23/26) and NBIA
(69.2%, 18/26). Over 70% of the countries had ter-
tiary centres for the management of these diseases. As
for group 2-ATX/HSP, 90.5% (19/21) of the countries
had ataxia/HSP experts and 61.9% (13/21) had ter-
tiary centres for these diseases. In group 3-AP, there
were experts in all three types of atypical parkinson-
ism in 72.2% (13/18) of the countries and there were
tertiary centres for management of these conditions in
83.3% (15/18) of the countries. Group 4-C had HD
experts in all countries (100%, 14/14) and also tertiary
centres for its management.
Networking. In group 1-DYS, networking was frequent
for dystonia (73.1%) but uncommon in paroxysmal
dyskinesias (26.9%) or NBIA (42.3%). Around 40% of
the respondents said that there was a networking group
in ataxia/HSP and in atypical parkinsonism. Almost all
experts of group 4-C answered that there was a net-
working group (86%) in their countries.
Ancillary tests. In group 1-DYS, magnetic resonance
imaging was available in all countries. Neurophysio-
logical tests were available except in two countries.
Genetic testing was accessible in 96.2% (25/26) of the
countries, but with some difficulties in 46.2% (12/26)
due mainly to economic reasons and too few geneti-
cists. Countries with better accessibility were Belgium,
Czech Republic, Denmark, Germany, Ireland, Italy,
Sweden, Finland, France, Norway, Netherlands and
Portugal. However, some of these countries also had
some limitations such as, for example, a fixed number
of tests allowed to be done, and others presented diffi-
culties in accessing more sophisticated techniques such
as next-generation sequencing (NGS).
In group 2-ATX/HSP, genetic and metabolic inves-
tigations were accessible with some difficulty in 47.6%
(10/21) and 57.1% (12/21) of the countries, respec-
tively. The main problems were economic reasons like
no insurance coverage, too few centres performing the
tests and long waiting lists. Neurophysiological tests
and neuroimaging were 100% available.
In group 3-AP, magnetic resonance imaging and
neuropsychological testing were available in all the
countries (19/19). Dopamine transporter single-photon
emission computed tomography and fluorodeoxyglu-
cose positron emission tomography were not available
in two countries, with the single-photon emission
computed tomography test more easily accessible than
positron emission tomography (68.4%, 13/19 vs.
31.6%, 6/19) in the others. The possibility of consult-
ing a sleep specialist or an ear, nose and throat spe-
cialist was available for all countries except Romania,
according to the respondents.
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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In group 4-C, genetic testing, counselling and pre-
natal testing were available in all countries. Pre-im-
plantation genetic diagnosis and exclusion pre-
implantation genetic diagnosis were rarely or not
available in Austria and Lithuania.
Treatment availability. In group 1-DYS, oral drugs
such as anticholinergics, antiepileptics, benzodi-
azepines, antidopaminergic drugs and levodopa were
easily available (>85 %) in most countries. The access
to dopaminergic blockers (tetrabenazine) was easy in
69.2% (18/26), with some difficulties in 26.9% (7/26)
and not available in 3.8% (1/26) of the countries.
Botulinum toxin was accessible in all countries but in
30.8% (8/26) with some difficulties. Finally, deep
brain stimulation (DBS) was easily accessible in
53.8% (14/26), accessible with some difficulties in
38.5% (10/26) and not available in 7.7% (2/26).
In group 2-ATX/HSP, anti-spasticity treatment (e.g.
botulinum toxin injections, intrathecal baclofen) was
available in all countries but with some difficulties in
47.6% (10/21).
In group 3-AP, levodopa (100%, 19/19), midodrine
(66.7%, 12/18) and fludrocortisone (89.5%, 17/19)
were widely available. Botulinum toxin was available
in all countries but with limitations in some of them
(33.3%, 6/18).
Finally, in group 4-C, drugs such as antipsychotics,
antidepressants, benzodiazepines and antiepileptics
were widely and easily available.
Physiotherapy, occupational therapy and language
therapy were available in all groups but with some
difficulties in 45%–50% of countries. The main prob-
lem in terms of accessibility to these therapies were
long waiting lists, lack of reimbursement, no possibil-
ity of chronic treatment and low number of expert
allied healthcare professionals focused on the specific
disorders.
Implementation of three main measures to improve the
management
Responding to the question ‘which are the three main
measures to improve the management of the respec-
tive RND patients’, the following seven measures
(from a total of 119) were identified to be the most
important ones to be implemented in European coun-
tries:
1) Development of multidisciplinary teams composed
of neurologists, geneticists, rehabilitation physi-
cians, specialized nurses, psychologists, physiother-
apists, speech and language and occupational
therapists. Patients should be visited at least one
time by these teams. Responders also claimed for
better access to rehabilitation therapies (n: 29/119)
2) Implementation of educational activities to
enhance recognition of rare MDs amongst health-
care professionals and in the general population (n:
24/119)
3) Improvement of the accessibility to standard and
advanced genetic testing and to clinical geneticists
(n: 16/119)
4) Development of more dedicated tertiary centres
and more expertise in the field (n: 9/119)
5) Facilitation of access to botulinum toxin and DBS
centres, and reimbursement of these treatments (n:
9/119)
6) Better access to international therapeutic trials and
promotion of clinical research (n: 9/119)
7) Development of national guidelines, which match
financial realities (n: 8/119)
Discussion
This study explores the management of different
RNDs in the field of MDs and the care needs of
European countries, in terms of patient accessibility,
networking, availability of therapies and ancillary
tests, research and training for different type of
healthcare professionals. Overall, the main concerns
of the respondents were related to limited education
for healthcare professionals, limited numbers of
experts and multidisciplinary teams, the need to pro-
mote clinical trials, limited access to genetic testing
and limited availability of various therapeutic options.
Diagnosing rare MDs is often challenging and
requires increased awareness and skilled experts. So,
accessibility to these experts and training not only for
neurologists but also for residents, general practition-
ers and other healthcare providers are essential. How-
ever, our results brought to light that the accessibility
for patients to experts was difficult in 20%–35% of
the countries and only about a quarter of the coun-
tries considered it easy. The main reasons for difficult
accessibility, according to the respondents, were the
small number of experts in these disorders and the
lack of knowledge amongst non-expert clinicians.
Moreover, some countries did not have experts in cer-
tain diseases such as NBIA, paroxysmal dyskinesia,
ataxias or atypical parkinsonism. Regarding training
in MDs, almost all countries had MD experts and
teaching courses or symposia in MDs for residents
and general neurologists. However, MD teaching
courses for general practitioners, nurses, physiothera-
pists and speech therapists were rarely provided. In
many countries, primary care physicians and general
neurologists are part of the first circle of care of the
patient. This means that it is important to disseminate
knowledge not only to MD experts but also to all
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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other care providers. With technological progress,
continuing education and on-the-job training are
paramount to keep existing skills in line with new
developments for all the professionals involved.
Patients with RNDs require multidisciplinary manage-
ment. Multidisciplinary teams should consider the
participation of all the professionals aforementioned
in point 1 of the implementation measures but the
role of other healthcare professionals such as psychia-
trists and social workers should also be considered.
The low prevalence of individual RNDs makes net-
working an important tool to support patients and
families and to promote exchange of information,
training and research [6]. However, according to the
respondents, networking groups were only present in
less than 45% of the countries for paroxysmal dyski-
nesia, NBIA, ataxia/HSP and atypical parkinsonism.
In contrast, for dystonia and HD, networking was
present in over 70% of the countries.
Regarding ancillary tests, genetics play a key role in
RNDs. About 80% of these diseases have a genetic
basis [7]. A definitive molecular diagnosis facilitates
the access to healthcare resources, reduces uncertainty
in patients and families, and provides accurate recur-
rence risk counselling [3]. However, our results show
that the accessibility to genetic testing is not satisfac-
tory in many European countries. In particular,
experts from groups 1-DYS and 2-ATX/HSP high-
lighted the need for better access to genetic tests and
advanced techniques such as NGS. NGS procedures
allow massive-scale DNA sequencing. In recent years,
several studies have shown that NGS is more cost-ef-
fective and can increase diagnostic yield in certain
patients compared with other more restricted sequenc-
ing technologies [8,9]. However, a majority of the
respondents find it difficult to access these advanced
technologies mainly due to financial reasons and to
the low number of genetic centres and a shortage of
geneticists. Moreover, it is well known that results
from NGS are difficult to interpret given the vast
quantities of sequencing data generated including vari-
ants of unpredictable meaning [10]. Neurologists and
residents must familiarize themselves with this
advanced technology, but it is crucial to promote the
formation of more geneticists who will handle this
complex technology and genetic counselling. Guideli-
nes for genetic evaluation and a consensus on when to
stop when a mutation is not found are also important
to define.
With regard to treatment, the results showed that
oral drugs were easily available with the exception of
tetrabenazine that was available in most of the coun-
tries but with some difficulties. Regarding botulinum
toxin in group 1-DYS, the results were similar to
those indicated in the paper published by Valadas
et al. in 2016 [5]. This treatment was accessible in all
countries but in 30.8% with some difficulties, mainly
related to financial issues like reimbursement. More
invasive treatments like DBS were more difficult to
access or absent in some countries.
Treatment access becomes even more important as
advanced therapies such as adeno-associated virus
based gene therapy and antisense oligonucleotides are
being developed for a number of RNDs [11]. Given
the high costs and complexity of these therapies, the
ERN-RND centres that have been acknowledged to
be able to provide highly specialized care for RND
patients might thus be considered as a suitable means
to provide equal, high quality and diligently moni-
tored access to such advanced therapies.
Neurological rare diseases tend to be chronic and
patients present neurological deficits that require a
multidisciplinary approach. These RNDs are very
heterogeneous and complex, with some symptoms
exceeding movement abnormalities, including dyspha-
gia, language problems and nutrition deficits. So it
seems that the installation of specific therapies by
trained professionals for these problems is necessary.
However, the results of the survey showed that acces-
sibility to these experts was difficult in more than a
half the countries. Although more studies with proper
methodology and long follow-up for non-pharmaco-
logical therapies are needed, some of them suggest
they can provide benefit and improvement of the
patient’s quality of life [12–14]. Acknowledging the
importance of non-pharmacological therapies for
RNDs, the ERN-RND decided to form a specific
working group for neurorehabilitation at its last
Board meeting in November 2019.
The ERN-RND has been established as an exper-
tise-driven and healthcare-focused network in order to
improve (i) access to high quality RND care, (ii) the
sharing of RND knowledge and data, as well as (iii)
the operation of multidisciplinary teams to provide e-
consultation (through the Clinical Patient Manage-
ment System, http://www.ern-rnd.eu/cpms/) to care
professionals who seek support for their respective
rare and complex RND patients. In fact, a European
network is able to address key rarities (i.e. care needs)
which are linked to the very problem of rare diseases
such as rarity of experts, missing knowledge and data
as well as missing training opportunities. However,
without a systematic, sustainable and financed integra-
tion of the ERN into the national healthcare systems
of the EU, achievements, synergies and impacts will
not bring about the required effect and will remain
dependent on the volatile motivation of participating
hospitals and experts.
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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This study has some limitations. First, the survey
did not cover palliative care issues. Taking into
account that rare neurological disorders often have
very complex needs that are amenable to a palliative
approach, this should have been a relevant care need
to explore. Secondly, although a large proportion of
countries of the EU were included in the study, some
of the groups presented a lower rate of respondents.
Thirdly, the results were based on a single subject
response per country and per group of diseases. This
might have biased the results of care needs. However,
all respondents were well-known physicians and they
were likely to be well informed about the management
of these disorders in their respective country. Further-
more, in particular with focus on the main measures
that were identified to address care needs, the com-
monalities across disease groups and EU countries
were striking.
In conclusion, the management of these conditions
in EU countries is unequal. Variations in diagnosis,
care and treatment may impact directly on patients’
outcomes. This survey offers insights into the current
unmet needs of healthcare professionals and patients
with these RNDs in Europe and should be considered
for healthcare decisions.
The survey has a high informational value for the
ERN-RND and will thus inform planning and opera-
tion of the ERN-RND for the forthcoming years. It
provides evidence that a European care-focused net-
work that is able to address the unmet RND care
needs and inequalities is highly warranted.
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